Trial Profile
Phase II Study of Imatinib Mesylate in Chordoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chordoma
- Focus Therapeutic Use
- Sponsors Novartis
- 17 Feb 2012 Results reported in the Journal of Clinical Oncology indicate that imatinib has some antitumor activity in this orphan disease and is worthy of further investigation.
- 02 Sep 2011 Additional location (Switzerland) identified as reported by ClinicalTrials.gov.
- 26 Feb 2009 Actual patient number (55) added as reported by ClinicalTrials.gov.